Pfizer Extends Partnership With Israeli Drug Development Firm CytoReason
CytoReason built a machine learning platform that can quantify a person’s immune system in order to better understand disease responses.
February 15, 2022
Israeli Biotech Startup CytoReason Teams Up With Swiss Pharma Firm Ferring For IBD Drugs
CytoReason said it plans to present insights on the top drug targets to provide new therapeutic options for IBD patients.
May 25, 2021
Israeli MIT Professor Wins $1M Prize For AI Work In Cancer Diagnostics, Drug Development
Professor Regina Barzilay is being honored for her work using ML models to detect and predict cancer, and accelerate drug development.
September 23, 2020
Israeli Biotech Startup Combines Immunology, AI To Help Develop Better Drugs
Founded in 2016, CytoReason already has partnerships with top global pharmaceutical companies.
May 14, 2019
Data-Powered Drug Discovery Startup CytoReason Signs Deal With Pfizer
The company's propriety platform combines scientific and experimental data for immune system simulations applicable to cancer immunotherapy, and autoimmune, neurodegenerative and infectious disease research.
January 08, 2019
Scientists Harness AI, Deep Learning To Fast-Track Drug Discovery And Development
Israeli data researchers, including Dr. Kira Radinsky, say they developed a system that will significantly shorten drug development time and reduce costs.
September 10, 2018